
Veniz XR75 mg
Sun Pharmaceutical Ltd.
Venlafaxine Hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for the following conditions: Established / FDA-approved uses Major Depressive Disorder (MDD) in adults.
Venlafaxine Hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) indicated for the following conditions:
The decision to use Venlafaxine Hydrochloride for any indication should be made by a qualified physician after weighing the potential benefits against risks.
| Population | Dose |
|---|---|
| Adults (Immediate-release) | Initial 75 mg/day in 2-3 divided doses with food; may increase gradually every 4 days or more, up to 225 mg/day (up to 375 mg/day in severe, hospitalized cases per physician judgment). |
| Adults (Extended-release) | Initial 75 mg once daily; may start at 37.5 mg/day for 4-7 days to improve tolerability. May increase in increments of up to 75 mg/day at intervals of no less than 4 days, up to a maximum of 225 mg/day. |
Extended-release formulation: Initial 75 mg once daily (37.5 mg/day for the first 4-7 days for panic disorder). May be titrated as needed up to 225 mg/day based on response and tolerability.
Dose reduction of approximately 25% is recommended in mild-to-moderate renal impairment; a reduction of approximately 50% is recommended in patients on hemodialysis. Doses should be withheld until the next scheduled dialysis session.
Dose reduction of approximately 50% is recommended in patients with mild-to-moderate hepatic impairment; greater reduction may be needed in severe impairment, and use with caution.
Abrupt discontinuation should be avoided. When stopping Venlafaxine Hydrochloride after more than 1 week of use, the dose should be tapered gradually over at least 2 weeks (longer if used for an extended period), under physician supervision, to reduce the risk of discontinuation symptoms.
Common side effects of Venlafaxine Hydrochloride include:
Serious but less common effects include serotonin syndrome, activation of mania/hypomania, seizures, abnormal bleeding, hyponatremia (especially in elderly patients), and increased suicidal thinking/behavior in children, adolescents, and young adults (see Precautions and Warnings).
Venlafaxine Hydrochloride is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.